TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01249469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin whitening cosmetic product
Description: Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: skin whitening cosmetic product
Description: Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand
Study: NCT02312856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseRider
Description: Adjunctive device for endovascular embolization of intracranial aneurysms
Study: NCT01892345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Induction Phase: 900 mg IV weekly for 4 weeks, followed by 1200 mg for the fifth dose; Maintenance Phase: 1200 mg IV every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Induction Phase: matching placebo (900 mg) IV weekly for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose; Maintenance Phase: matching placebo (1200 mg) IV every 2 weeks
Study: NCT01488708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.
Study: NCT03819582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeCee One intraocular lens
Description: Hydrophobic aspheric monofocal intraocular lens
Study: NCT00615381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: insulin infusion (0-10 U/hr) vs. 0.3 U/kg/hr and boluses (0-8 U) adjusted every 15 minutes during the intraoperative period to maintain intraoperative euglycemia (blood glucose levels 80-120 mg/dL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: insulin infusion (0-10 U/hr) vs. 0.3 U/kg/hr and boluses (0-8 U) adjusted every 15 minutes during the intraoperative period to maintain intraoperative euglycemia (blood glucose levels 80-120 mg/dL)
Study: NCT04590586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.
Study: NCT00425815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 24448
Description: Org 24448 is a moderate-potency selective AMPA positive modulator that enhances the glutamate system in the brain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 24448
Description: Org 24448 is a moderate-potency selective AMPA positive modulator that enhances the glutamate system in the brain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparison
Study: NCT01363037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Vaginal Ring
Description: dosage form: dapivirine vaginal ring dosage:25 mg frequency:continuous use duration:28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc Vaginal Ring
Description: dosage form: maraviroc vaginal ring dosage:100 mg frequency:continuous use duration:28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal Ring
Description: dosage form: placebo vaginal ring dosage:N/A frequency:continuous use duration:28 days
Study: NCT01363037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine-Maraviroc Vaginal Ring
Description: dosage form: combination vaginal ring dosage:25 mg dapivirine + 100 mg maraviroc frequency:continuous use duration:28 days
Study: NCT05150509

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Squamous Cell Carcinoma
Description: To identify the association of elevated level of specific amino acids in OSCC by Liquid Chromatography Mass Spectrometry
Study: NCT04590586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.
Study: NCT00810368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carnosine
Description: 500mg Carnosine x2 daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose placebo tablets x2 daily
Study: NCT03915938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: S-ketamine will be administered in precalculated infusion rates to obtain a plasmatic level of 60 ng/ml
Study: NCT04590586

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast administered orally as a tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast placebo
Description: Matching apremilast placebo administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Lanadelumab administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lanadelumab placebo
Description: Matching lanadelumab placebo (normal saline) administered as an intravenous (IV) infusion.
Study: NCT03915938

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered in an identical way than ketamine.
Study: NCT04590586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilucoplan
Description: Zilucoplan administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zilucoplan placebo
Description: Matching zilucoplan placebo administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
Study: NCT03892382

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex.
Study: NCT03465618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging
Description: A low dose spiral CT is performed first per the standard procedure. These images will be used for both attenuation correction and registration of the serial image set. The initial PET brain scan will be acquired up to about 24 hours post injection. Based upon the discretion of the physician, non-surgical patients have the possibility of a second scan and third up to about 48 hours post injection. The times per bed position may be adjusted after the first patient is imaged, and his/her scans evaluated. Additional low dose CT scans will be performed at the image session for attenuation correction and image registration. PET study may be done on a PET-MR scanner for ease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging
Description: A low dose spiral CT is performed first per the standard procedure. These images will be used for both attenuation correction and registration of the serial image set. The initial PET brain scan will be acquired up to about 24 hours post injection. Based upon the discretion of the physician, non-surgical patients have the possibility of a second scan and third up to about 48 hours post injection. The times per bed position may be adjusted after the first patient is imaged, and his/her scans evaluated. Additional low dose CT scans will be performed at the image session for attenuation correction and image registration. PET study may be done on a PET-MR scanner for ease.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and Urine samples
Description: Venous blood and urine samples will be obtained at approximately 0.5 hours post injection at the end of each scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and Urine samples
Description: Venous blood and urine samples will be obtained at approximately 0.5 hours post injection at the end of each scan
Study: NCT01172223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myocet (Non-pegylated liposomal doxorubicin (NPLD))
Description: 60 mg/m\^2 i.v. day 1 q3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2 i.v. day 1 q3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib (GW572016, Tykerb)
Description: 750-1500 mg/d orally daily until the day of the definitive surgery
Study: NCT02269228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03830957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: 7.5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 7.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: 5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 5 mg
Study: NCT01567345

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable pump with continuous flow
Description: Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Continuous morphine's flow is scheduled.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable pump with programmable flow.
Description: Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Programmable morphine's flow is scheduled.
Study: NCT02531776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcutaneous insertions of needles
Description: Various types of needles with different designs and mechanical properties.~Five marketed needles are included: NovoFine 28G x 12 mm (Novo Nordisk A/S, Denmark), NovoFine 30G x 6 mm (Novo Nordisk A/S, Denmark), NovoFine 32G tip x 6 mm (Novo Nordisk A/S, Denmark), BD Ultra-Fine 32G x 4 mm Pentapoint (Beckton, Dickinson \& Company, USA), and Terumo Nanopass 34G x 5 mm (Terumo, Japan).~Ten needles have been exclusively manufactured for this clinical trial by Hart Needles, USA. These needles vary in diameter, number of needle tip grinding, and angles of grindings.~Three needles have been modified from the original (NovoFine 32G x 6 mm) with lack of lubrication or damaged needle tip for simulations of repeated use.~No drugs are injected. Only the needle insertion is evaluated.
Study: NCT01033955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Loading dose: 40 mg (day 1) Maintenance dose: 20 mg (days 2-14)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical appearing encapsulated placebo.
Study: NCT05183308

Intervention type: DRUG
Intervention: Clodronic Acid
Description: Osteoporotic fracture treated with surgical and medical therapy
Study: NCT03921840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ELDERFITNESS
Description: In person training: Participants will receive a 2-hour in person education session with the exercise trainer. Self-monitoring: Subjects will self-monitor subjects' level of physical activity (steps \& minutes of moderate activity) using the smartwatch. The Google calendar and Fitbit apps will send messages and alerts to the subject's smartwatch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer.~Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans. Financial incentives: The intervention will include financial incentives. Specifically, when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: General education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life program book from the National Institute on Aging.
Study: NCT03628131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
Study: NCT02053142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir
Description: Single dose of acyclovir 200mg was given for pk study
Study: NCT03273244

Intervention type: DEVICE
Intervention: NeuroSense monitoring and ANI monitoring
Description: From the start of palliative sedation, monitoring of EEG with NeuroSense device (WAVcns: Wavelet Anesthetic Value of the Central Nervous System) and ANI-monitoring (Analgesia Nociception Index) will be initiated.
Study: NCT03532009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate
Description: Oral use for approximately 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral use for approximately 3 months
Study: NCT03653195

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: urine metabolomics
Description: We aim to determine of a specific urine metabolomic biomarkers can diagnose concussion.

Intervention type: OTHER
Group type: OTHER
Intervention: urine metabolomics
Description: We aim to determine of a specific urine metabolomic biomarkers can diagnose concussion.
Study: NCT02053142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Single dose of acyclovir 200mg was given for pk study
Study: NCT04464226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (Nubeqa, BAY1841788)
Description: Participants will continue receiving darolutamide treatment at the dose level and schedule of administration previously assigned in the feeder study.
Study: NCT01300325

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 3% hypertonic saline solution
Description: Patients receive every 6 hours the nebulized 0.9% saline (Placebo comparator) (group I) or the 3% hypertonic saline solution group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
Study: NCT01005303

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 Tablet Daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forceval plus 50 micrograms Vitamin D3
Description: Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily
Study: NCT02701335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural mobilization
Description: The first 6 exercises consist of active range of motion movements of the hand designed to improve joint flexibility. The remaining 3 exercises are designed to strengthen grip and pinch by using a non-latex polymer ball: the Thera-Band Hand Exerciser (The Hygenic Corporation, Akron, OH) Subjects began with 10 repetitions the first 4 sessions, progressed to 12 repetitions the next 2 sessions, then 15 (2 sessions), and finally 20, if able, during the last sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gloreha device
Description: Robotic assisted passive mobilization.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standardized exercise
Description: 9 exercises: active range of motion, strengthen grip and pinch

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standardized exercise
Description: 9 exercises: active range of motion, strengthen grip and pinch
Study: NCT02053142

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03242876

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control will be 109 g white bread to be consumed together with 200 mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test
Description: Test will be 109 g white bread to be consumed together with 3.819 g citric acid and 119 mg malic acid dissolved in 200 mL water adjusted to pH 3.2.
Study: NCT03901833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Support
Description: Telemedicine intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study: NCT03778931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: 400 mg/day once daily oral dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: * Fulvestrant: 500 mg administered intramuscularly (IM) into the buttocks as two 5 mL injections on C1D1, C1D15 and C2D1 and Day 1 of every subsequent 28-day cycle~* Anastrozole 1 mg/day on a continuous dosing schedule~* Letrozole: 2.5 mg/day on a continuous dosing schedule~* Exemestane: 25 mg/day on a continuous dosing schedule
Study: NCT03297606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300mg taken twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 100mg administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab
Description: * Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase.~* Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5mg orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 500mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: 250mg orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 25mg infused over a 30-60 minute period once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150mg orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus Pertuzumab
Description: Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion.~Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib plus Cobimetinib
Description: Vemurafenib = 960 mg orally every 12 hours.~Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: 150mg taken orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: 300mg taken orally, twice daily
Study: NCT03680664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 mA (current density = 0.57 A/m2) for 30 min per day.
Study: NCT02836574

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Renal Autologous Cell Therapy (REACT)
Description: Autologous selected renal cells (SRC).
Study: NCT03680664

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice.